Of note, glycemic and body weight loss responders show a higher reduction in Hcy level than non-responders.<h4>Conclusions</h4>Glycemic control and body weight loss, and hence amelioration of Hcy level by Vilda as add-on therapy to Met in Egyptian T2DM obese patients are subjected to genetic variation in one or more of the DPP-4, GLP1R and KATP genes involved in Vilda's modes of action. Here, GLP1R is linked to type 2 diabetes mellitus.